13 results
8-K
EX-99.2
GLYC
GlycoMimetics Inc
4 Apr 14
GlycoMimetics Reports Fourth Quarter and Year-End 2013 Results
12:00am
administration. During his tenure at MedImmune, Mr. Pearson was a key leader in a number of MedImmune’s financing and M&A transactions, including its $500 million
8-K
EX-99.2
GLYC
GlycoMimetics Inc
5 Aug 21
Glycomimetics Reports Highlights and Financial Results
8:01am
in AML. During his 16-year tenure at Novartis, Mr. Semerjian held both strategic and operational leadership roles including US Hematology franchise head
8-K
GLYC
GlycoMimetics Inc
5 Aug 21
Glycomimetics Reports Highlights and Financial Results
8:01am
, culminating in his last role as Senior Vice President, Global Head for Ribociclib, accountable for worldwide launch preparations. During his tenure at Novartis
PRE 14A
GLYC
GlycoMimetics Inc
22 Mar 24
Preliminary proxy
5:00pm
and global head for Ribociclib, accountable for worldwide launch preparations. During his tenure at Novartis, Mr. Semerjian worked on numerous launches … Committee reviews these directors’ overall service to the Company during their tenure as a director, including the number of meetings attended, level
S-1
EX-3.5
5sn8x p3wgmdbugdu
4 Oct 13
IPO registration
12:00am
8-K
EX-3.2
r58788ldsa5hs
15 Jan 14
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
EX-10.1
auop1krcd6mppv
28 Jul 14
Entry into a Material Definitive Agreement
12:00am
- Prev
- 1
- Next